Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger

OBJECTIVE: To assess long‐term efficacy and safety of canakinumab and the response to vaccination in children ages ≤5 years with cryopyrin‐associated periodic syndrome (CAPS). METHODS: CAPS patients (ages ≤5 years) received 2 mg/kg canakinumab subcutaneously every 8 weeks; patients with neonatal‐ons...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Arthritis Rheumatol
Prif Awduron: Brogan, Paul A., Hofer, Michael, Kuemmerle‐Deschner, Jasmin B., Koné‐Paut, Isabelle, Roesler, Joachim, Kallinich, Tilmann, Horneff, Gerd, Calvo Penadés, Inmaculada, Sevilla‐Perez, Belén, Goffin, Laurence, Lauwerys, Bernard R., Lachmann, Helen J., Uziel, Yosef, Wei, Xiaoling, Laxer, Ronald M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2019
Pynciau:
Pediatric Rheumatology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6899890/
https://ncbi.nlm.nih.gov/pubmed/31161734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.41004
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg